Anoopum Gupta, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebellar Ataxia | 6 | 2023 | 150 | 2.690 |
Why?
|
| Ataxia Telangiectasia | 5 | 2023 | 107 | 2.660 |
Why?
|
| Ataxia | 12 | 2023 | 306 | 2.110 |
Why?
|
| Parkinsonian Disorders | 2 | 2021 | 284 | 1.140 |
Why?
|
| Dysarthria | 2 | 2023 | 58 | 1.080 |
Why?
|
| Pursuit, Smooth | 1 | 2020 | 38 | 0.730 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 220 | 0.720 |
Why?
|
| Eye Movements | 3 | 2023 | 509 | 0.650 |
Why?
|
| Parkinson Disease | 3 | 2022 | 2875 | 0.640 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2024 | 1468 | 0.520 |
Why?
|
| Paresis | 1 | 2015 | 176 | 0.470 |
Why?
|
| Aphasia | 1 | 2015 | 192 | 0.450 |
Why?
|
| Neurology | 1 | 2022 | 778 | 0.450 |
Why?
|
| Cerebellum | 1 | 2020 | 1500 | 0.430 |
Why?
|
| Maze Learning | 2 | 2012 | 482 | 0.430 |
Why?
|
| Muscle Weakness | 1 | 2015 | 413 | 0.410 |
Why?
|
| Spinocerebellar Ataxias | 2 | 2022 | 104 | 0.370 |
Why?
|
| Theta Rhythm | 1 | 2012 | 219 | 0.350 |
Why?
|
| Spatial Behavior | 1 | 2010 | 88 | 0.340 |
Why?
|
| Consensus | 3 | 2023 | 3115 | 0.330 |
Why?
|
| Hippocampus | 2 | 2012 | 3755 | 0.310 |
Why?
|
| Disease Progression | 4 | 2023 | 13484 | 0.300 |
Why?
|
| Movement | 2 | 2022 | 1478 | 0.240 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2023 | 44 | 0.210 |
Why?
|
| Ankle | 2 | 2023 | 349 | 0.210 |
Why?
|
| Friedreich Ataxia | 1 | 2023 | 77 | 0.200 |
Why?
|
| Gait | 3 | 2022 | 816 | 0.200 |
Why?
|
| Behavior, Animal | 1 | 2010 | 1877 | 0.200 |
Why?
|
| Multiple System Atrophy | 1 | 2022 | 129 | 0.180 |
Why?
|
| Wrist | 1 | 2022 | 227 | 0.180 |
Why?
|
| Speech Disorders | 1 | 2021 | 180 | 0.180 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 144 | 0.180 |
Why?
|
| Memory | 1 | 2010 | 2182 | 0.170 |
Why?
|
| Speech | 2 | 2023 | 553 | 0.170 |
Why?
|
| Delphi Technique | 1 | 2023 | 835 | 0.170 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 20078 | 0.160 |
Why?
|
| Neurofilament Proteins | 1 | 2021 | 336 | 0.160 |
Why?
|
| Motor Neurons | 1 | 2023 | 868 | 0.150 |
Why?
|
| Uncertainty | 1 | 2023 | 753 | 0.150 |
Why?
|
| Headache | 2 | 2016 | 1252 | 0.150 |
Why?
|
| Computers | 1 | 2019 | 596 | 0.140 |
Why?
|
| Methylphenidate | 1 | 2020 | 488 | 0.130 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2016 | 50 | 0.130 |
Why?
|
| Lethargy | 1 | 2015 | 43 | 0.130 |
Why?
|
| Humans | 25 | 2024 | 760437 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2023 | 1199 | 0.120 |
Why?
|
| Diplopia | 1 | 2016 | 215 | 0.120 |
Why?
|
| Child, Preschool | 4 | 2022 | 42209 | 0.120 |
Why?
|
| Child | 5 | 2023 | 80086 | 0.110 |
Why?
|
| Rats, Inbred BN | 1 | 2012 | 231 | 0.100 |
Why?
|
| Young Adult | 5 | 2022 | 59068 | 0.100 |
Why?
|
| Motor Activity | 1 | 2021 | 2710 | 0.090 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 825 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 13312 | 0.090 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 1857 | 0.090 |
Why?
|
| Brain | 2 | 2022 | 27060 | 0.090 |
Why?
|
| Adolescent | 4 | 2022 | 88196 | 0.080 |
Why?
|
| Leukemia | 1 | 2015 | 1522 | 0.070 |
Why?
|
| Adult | 8 | 2024 | 220781 | 0.070 |
Why?
|
| Male | 10 | 2024 | 360035 | 0.060 |
Why?
|
| Rats | 2 | 2012 | 23712 | 0.060 |
Why?
|
| Action Potentials | 1 | 2010 | 1830 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2010 | 1765 | 0.050 |
Why?
|
| Ocular Motility Disorders | 1 | 2023 | 144 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 13338 | 0.050 |
Why?
|
| Aged | 5 | 2024 | 168840 | 0.050 |
Why?
|
| Receptors, GABA | 1 | 2022 | 311 | 0.040 |
Why?
|
| Intermediate Filaments | 1 | 2021 | 172 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2022 | 656 | 0.040 |
Why?
|
| Postural Balance | 1 | 2021 | 621 | 0.030 |
Why?
|
| Middle Aged | 5 | 2024 | 220382 | 0.030 |
Why?
|
| Female | 5 | 2024 | 391875 | 0.030 |
Why?
|
| Decision Making | 1 | 2010 | 3923 | 0.030 |
Why?
|
| alpha-Synuclein | 1 | 2022 | 750 | 0.030 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2015 | 64 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2015 | 6831 | 0.030 |
Why?
|
| Piracetam | 1 | 2015 | 88 | 0.030 |
Why?
|
| Nootropic Agents | 1 | 2015 | 157 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 58859 | 0.030 |
Why?
|
| Animals | 3 | 2022 | 168253 | 0.030 |
Why?
|
| Self Report | 1 | 2024 | 3721 | 0.030 |
Why?
|
| Craniotomy | 1 | 2015 | 741 | 0.020 |
Why?
|
| Neurons | 1 | 2010 | 9443 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5236 | 0.020 |
Why?
|
| Fever | 1 | 2016 | 1618 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 1841 | 0.020 |
Why?
|
| Genotype | 1 | 2023 | 12976 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 1944 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 7996 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 14565 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8611 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 1517 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10180 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 12969 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41366 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 64591 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20551 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 36362 | 0.000 |
Why?
|